Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence

Authors

  • D. Micheloud,

    1. Unidad de Investigación, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain,
    Search for more papers by this author
  • M. Salcedo,

    1. Unidad de Trasplante Hepático, Hospital General Universitario ‘Gregorio Marañón,’ Madrid, Spain,
    2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain,
    Search for more papers by this author
  • R. Bañares,

    1. Unidad de Trasplante Hepático, Hospital General Universitario ‘Gregorio Marañón,’ Madrid, Spain,
    2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain,
    Search for more papers by this author
  • D. Rincón,

    1. Unidad de Trasplante Hepático, Hospital General Universitario ‘Gregorio Marañón,’ Madrid, Spain,
    2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain,
    Search for more papers by this author
  • R. Lorente,

    1. Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario ‘Gregorio Marañón,’ Madrid, Spain
    Search for more papers by this author
  • M.A. Muñoz-Fernández,

    1. Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario ‘Gregorio Marañón,’ Madrid, Spain
    Search for more papers by this author
  • S. Resino

    1. Unidad de Investigación, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain,
    Search for more papers by this author


Salvador Resino, Unidad de Investigación, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2, 28220 Majadahonda, Madrid, Spain
Tel: +34 918 223 266
Fax: +34 915 097 946
E-mail: sresino@isciii.es

Abstract

Abstract: This prospective study analyzed the relationship between several biological markers related to liver fibrosis at 3 months and 1 year post liver transplantation in 37 patients (19 with hepatitis C virus [HCV], 18 with alcoholic liver disease). Severe HCV recurrence (HCV-SR) was defined as fibrosis stage ≥F1 (METAVIR score) at 1 year and/or a value of hepatic venous pressure gradient ≥6 mmHg. We found HCV-SR patients had higher values of monocyte chemotactic protein-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and hyaluronic acid (HA) than non-severe HCV recurrence patients (P<0.05). Moreover, receiver operating characteristic curve analysis showed that interferon-inducible protein 10 (IP-10) (area under the curve [AUC]: 0.74; confidence interval [CI] 95%: 0.49–0.91; P=0.043), MCP-1 (AUC: 0.78; CI 95%: 0.54–0.94; P=0.007), sVCAM-1 (AUC: 0.89; CI 95%: 0.67–0.98; P=0.005), and HA (AUC: 0.80; CI 95%: 0.55–0.94; P=0.035) have good predictive capacity for identifying severe HCV infection. The evaluation of these biomarkers may be useful in the early identification of patients in whom a more aggressive therapeutic approach could be necessary.

Ancillary